[New antibiotics: an overview].

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Antibiotic resistance is a growing global health crisis, necessitating novel therapeutic strategies.
• Older antibiotics are being re-evaluated for efficacy against multidrug-resistant bacteria.
• New classes of antibiotics, including glycopeptides and oxazolidinones, have emerged.

Purpose of the Study:

• To review current advancements in antimicrobial drug development.
• To highlight the renewed interest in older antibiotics for resistant infections.
• To discuss new therapeutic options for Gram-negative and Gram-positive bacterial infections.

Main Methods:

• Review of recent clinical and preclinical research on antibiotic efficacy.
• Analysis of newly registered antimicrobial agents and combination therapies.
• Examination of investment trends and regulatory processes in antimicrobial development.

Main Results:

• Several new antibiotics (oritavancin, dalbavancin, tedizolid) are approved for skin infections.
• Combination therapies (e.g., cephalosporins with beta-lactamase inhibitors) show effectiveness against resistant Gram-negative bacteria.
• Preclinical data for new antibiotics are encouraging, with increased R&D investment.

Conclusions:

• There is a renewed focus on developing and utilizing antibiotics to combat resistance.
• New agents and strategies offer hope for treating challenging bacterial infections.
• Accelerated regulatory pathways are facilitating the availability of urgently needed antimicrobials.